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Abstract
Melanoma is the most dangerous form of skin cancer and its incidence has been
increasing in the United States. Most melanomas are resistant to current chemotherapies;
therefore, understanding the mechanism of melanomagenesis is beneficial to treatment of
the diseases. Accumulation of β-catenin has been shown in colon and other cancers,
including melanomas, but the transcriptional role of β-catenin in melanomas is still
unclear. All-trans retinoic acid (ATRA) is an anti-tumor agent that has an inhibitory
effect on β-catenin, but this effect has not been studied in melanomas. It has been shown
that Microphthalmia-associated transcription factor (MITF), a melanocyte specific
protein, can redirect the function of β-catenin from cell proliferation to melanocytespecific gene expression. In addition, ATRA induced Mitf mRNA expression was
observed in mouse melanocyte. My objective is to understand the effects of ATRA on the
β-catenin signal pathway in ATRA-sensitive melanoma cells. I hypothesize that ATRA
will decrease β-catenin transcriptional activity. Western blotting was used to determine
the effects of ATRA on β-catenin target genes. Gel Shift assays were used to investigate
DNA/ protein interactions. Reporter gene assays were used to examine the effects of
ATRA on the transcriptional activity of β-catenin. Results showed a 20% and 40%
reduction in c-Myc protein expression after 2 days and 4 days ATRA treatment,
respectively. Cyclin D-1 protein expression was reduced by 40% after 4 days treatment
compared to the control. ATRA increased the protein levels of MITF after 2 days
treatment. Reporter gene assay showed that ATRA reduced transcriptional activity of
exogenous active β-catenin in human melanoma cells. Together, ATRA inhibits
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melanoma progression by reducing β-catenin transcriptional activity, and in part through
inducing MITF expression to alter the function of β-catenin away from growth regulatory
pathway.
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Chapter One
Introduction
According to estimates of the American Cancer Society, there will be over 60,000
new cases of melanoma in the United States each year. Melanoma is the most dangerous
form of skin cancer. Although melanoma only represents 5% of all skin cancers, it causes
71% of all skin cancer deaths (2). Melanoma is a malignant tumor that originates from
the pigment-producing skin cell, melanocytes. Melanoma, like some other cancers, has a
good prognosis if recognized and treated early. However, if it is not, melanoma can
metastasize to lymph nodes and other organs beyond the region of the original tumor.
The initial treatment of melanoma is usually by surgical excision, generally followed by
chemotherapy when treating later stage melanoma. However, the prognosis for survival
of the late stage melanoma patient is poor.

In order to find an effective treatment against melanoma or any other cancers, we
have to understand the molecular signaling pathways that govern tumor development and
survival. Therefore, we utilize all trans-retinoic acid (ATRA) as our inhibitor of
melanoma growth. Many studies have shown that ATRA can delay the progression of
some tumor cells, including melanoma, by inducing cell cycle arrest (32, 42). Thus, we
used the retinoid-sensitive B16 mouse melanoma cell line - F1 (low metastatic ability)
and F10 (high metastatic ability). Recent studies suggest that ATRA is capable of
inhibiting activation of β-catenin reporter constructs in vitro (56). Many studies have
shown that Wnt/ β-catenin pathway is activated in different types of cancer. In addition,
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accumulation of β-catenin in the nucleus of colon cancer cells contributes to
tumorigenesis. However, ATRA inhibition of β-catenin activity has not been studied in
melanoma. Therefore, β-catenin was selected as the molecule of interest, and
investigated the interaction of ATRA and β-catenin signaling in melanoma.
The role of β-Catenin was first recognized as a membrane-associated protein,
involved in cell–cell adhesion (21). Cytoplasmic β-catenin binds to the carboxyl
terminus of E-cadherin at the plasma membrane, and this complex recruits α-catenin, and
then further recruits other structural proteins to form the cell-cell junctions (17). In
addition to its role as an adhesion protein, β-catenin can also be a transcription
coactivator. β-catenin is a key component of downstream signaling in the Wnt/ Wingless
pathway, which is extremely important to embryonic development. This pathway is also
involved in disease development if mis-regulation of β-catenin occurs (34). In
development, Wnt protein binds to the Frizzled receptor and inhibited the adenomatous
polyposis coli (APC)/ Glycogen Synthase Kinase (GSK-3 β) complex, which
phosphorylates β-catenin, targeting it to proteasomal degradation. When β-catenin is
protected from degradation, it enters the nucleus and associates with the T-cell factor and
lymphoid enhancer factor (TCF/LEF-1) family of transcription factors. This association
activates the transcription of β-catenin target genes, including regulators of cell growth
and proliferation, modulators of cell death pathways and cell–cell communication (22).
If Wnt/ β-catenin pathway is activated inappropriately, then it might cause tumorigenesis.
Thus, this study is to focus on the regulation of the activity of β-catenin and its partner
TCF/ LEF-1 DNA binding proteins, by ATRA.
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Objective
Unlike the mouse B16 cells, many human melanomas are resistant to ATRA,
therefore we hope to use the mouse B16 cells to understand how the ATRA affects the βcatenin signal transduction pathway in a responsive melanoma model. I will focus on the
transcriptional activity of β-catenin and its partner signaling molecules in mouse B16
melanoma cells.

Hypothesis
Previously, we observed that ATRA reduces mouse B16 melanoma cell growth;
therefore, my hypothesis is the ATRA treated B16 mouse melanoma cells will have a
lower β-catenin transcriptional activity compared to the untreated B16 cells.
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Chapter Two
Review of Literature
Introduction
This chapter presents a review of the literature relevant to the present study. The Chapter
consists of three parts:
1.) The role of β-catenin and partner protein TCF/LEF in tumorigenesis;
2.) The β-catenin target genes related to cell proliferation, cell cycle regulation, and
melanocyte survival;
3.) The use of the anti-tumor agent, all trans-retinoic acid (ATRA).
The role of β-catenin and partner protein TCF/LEF protein in tumorigenesis
Activation of Wnt pathways can modulate cell proliferation, cell survival, cell
behavior, and cell fate. The core molecule of this pathway is β-catenin/ armadillo. A
series of signaling events occurs before β-catenin can function as a co-activator of gene
transcription. Generally, the Wnt pathway begins when secreted Wnt glycoproteins bind
to cell-surface receptors of the Frizzled family. This activates Dishevelled (DSH), a key
component of a membrane-associated Wnt receptor complex, which inhibits a second
complex of proteins that includes axin, GSK-3, and the protein APC. In absence of Wnt
signaling, APC-axin-GSK-3β complex phosphorylates β-catenin, and then ubiquitination
of β-catenin follows, which leads to proteosomal degradation of ubiquitin-tagged βcatenin. However, activated DSH deactivates this “β-catenin degradation complex”,
which leaves a pool of stabilized and active cytoplasmic β-catenin. High levels of
cytoplasmic β-catenin are able to rapidly migrate into the nucleus through gated channels.
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In the nucleus, active β-catenin couples with TCF/LEF family transcription factors to
promote specific gene expression (22, 34, 57).

In normal differentiated cells, β-catenin either associates with cadherins to form
cell-adhesive structures or is phosphorylated by the APC-axin-GSK-3β complex that
leads to its degradation by the ubiquitin-proteasome system (1, 40). It is known that the
Wnt/ β-catenin signaling pathway can cause tumorigenesis in colon cancer (44).
Tumorigenesis is thought to be initiated by mis-regulation or by mutations of β-catenin,
which disable regulatory phosphorylation. The ultimate goal of Wnt pathways are to
protect free and activate β-catenin and then activate gene transcription. A recent study
has shown that in mouse B16 cells, β-catenin mostly accumulates in cytoplasm and some
accumulation occurs in the nucleus. In contrast in human melanoma cells (501mel and
SK-MEL-5), β-catenin exhibits high levels of nuclear accumulation (49). This suggests
that the degree of β-catenin accumulation varies among melanoma cells. Alterations
other than dysregulation of Wnt signaling may also result in tumorigenesis. Stabilizing
mutations of β-catenin can also promote cancer development. Rimm et al. (1999)
showed that 6 of 27 melanoma cell lines were found to have β-catenin exon 3 mutations
affecting the N-terminal phosphorylation sites (37). In other studies, mutations of βcatenin in melanoma cell lines are rare; therefore, possibly other mechanisms of β-catenin
misregulation contribute to melanogensis.

β-catenin acts as a transcriptional coactivator for gene expression by forming a
complex with T-Cell Factor (TCF) proteins and regulating gene transcription. The TCF
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transcription factor family is a group of high mobility DNA binding proteins. In
mammals, there are four proteins in the family referred to as TCF/ LEF transcription
factors (LEF-1, TCF-1, TCF-3 and TCF- 4). These factors play a crucial role in
WNT/Wingless signaling, a signal transduction cascade that directs cell proliferation,
differentiation and survival. Mann et al. (1999) was able to show the direct interaction
between β-catenin and TCF/ LEF complex with the promoter region of c-jun and fra-1 in
a gel shift assay. Lymphoid Enhancer Factor -1 (LEF-1) is a protein that is expressed
during development in many different differentiating tissues and its function is sometime
redundant with TCF transcriptional factor. Interestingly, studies in melanoma suggested
that LEF-1 and β-catenin synergistically play a role in cancer progression. In the study of
Shtutman et al. (1999), they had found that in colon cancer cells, β-catenin couples with
LEF-1 and binds to the LEF-1 DNA binding site in the cyclin D1 promoter. In addition,
they showed that wild-type APC can prevent the coupling of β-catenin and LEF-1. They
concluded that the elevation of cyclin D1 in colorectal cancer promotes uncontrolled
proliferation and thus contributes to the neoplastic transformation of cells (38). LEF-1 is
thought to be the partner of β-catenin and the transcription factor that is involved in
melanoma progression (16, 37). Our previous data also suggest that B16 cells do not
express TCF-4.

Cyclin D1
To date, the transcriptional role of β-catenin in melanoma is still unclear, but
some studies have identified several genes that are β-catenin target genes. One of which
is cyclin D1, a key regulator of progression through the G1 phase during the cell cycle.
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Cyclin D1 is one of the three D-type cyclins, which are essential for progression from G1
to S-phase. These D cyclins bind to and activate both cyclin-dependent kinases (CDK4
and CDK6). The CDK are then activated due to phosphorylation by CDK-activating
kinase (CAK). The activated CDKs phosphorylate the retinoblastoma (Rb) protein,
which leads to release of the E2F (family of transcription factors (TF) in higher
eukaryotes) transcription factors and cells can then proceed to S phase (52). Due to
abnormal regulation of β-catenin in cancer cells, β-catenin accumulates inside the
nucleus, which results in the binding of β-catenin and LEF-1. This complex then binds to
the Lef-1 DNA binding site in the target genes’ promoter and initiates transcription.
Shtutman et al. (1999)have shown that β-catenin couples with LEF-1 protein and binds to
a LEF-1 binding site in the cyclin D1 promoter; thereby the cyclin D1 gene is a direct
gene expression target for β-catenin/LEF-1 in human colon cancer cells (43, 44, and 48).
Studies have also indicated that the cyclin D1-gene (CCND1) acts as an oncogene in
human hepatocellular carcinoma and esophageal cancer (20, 53). In addition, aberrant
expression of cyclin D1 is commonly displayed in human cancers (5, 45, and 47);
therefore, cyclin D1 would be a marker for cell proliferation.
c-Myc
c-Myc is a transcription factor in the basic Helix Loop Helix-Leucine Zipper
(bHLH-LZ) family. There are three members in Myc family: n-Myc, L-Myc and c-Myc.
They all possess the ability to induce cell proliferation, differentiation and tumorigensis.
Aberrant expression of the c-Myc gene has been found in several types of human tumors,
and the n-Myc gene is expressed/ overexpressed in tumors or cells that derived from
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neuroblastomas (31). Abnormal expression of the L-Myc gene has been found in human
small cell lung carcinomas (30). C-Myc plays a key role in up-regulation of the
transcription of growth-related genes. The mechanism of Myc transcriptional regulation
is thought to be by coupling with the Max protein to form a heterodimeric complex and
binding to target DNA binding sites to enhance transcription. Phosphorylation of c-Myc
by the p44/42 MAP kinase at Ser62 and Thr58 and Ser62 can resulted in activation (12).
Activation of c-Myc requires mitogenic signals such as Wnt, Sonic hedgehog homolog
(Shh), and epidermal growth factor (EGF). Therefore, Wnt/ β-catenin signaling can
induce c-Myc expression level. In addition, c- Myc is similar to cyclin-D1, in what it is
involved in cell proliferation, differentiation and apoptosis. It also has been shown that cMyc is one of the target genes of Wnt/ β-catenin in colorectal cancers (13). Therefore,
we chose c-Myc and cyclin D1 as molecules of interest.

MITF
Microphthalmia-associated transcription factor (MITF) is a basic helix-loophelix-leucine zipper (bHLH-LZ) protein encoded by the mouse microphthalmia locus. It
plays a vital role in differentiation and survival of melanocytes (14, 15). MITF is a down
stream target of β-catenin (8). Surprisingly, the bHLH-LZ region of MITF is shown to
bind to LEF-1 as a coactivator in its own transcriptional activation (41). In addition, the
interaction between LEF-1, not TCF-1, and MITF is detected in melanocytes. MITF was
also shown to up-regulate BCL2 (anti-BCL2 apoptotic protein) expression in pigment
cells (26), which could also be happening in melanoma cells. It is noteworthy that
GSK3-β, an inhibitor of β-catenin, can be activated by cAMP and then phosphorylates
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MITF, and therefore activates MITF (27). One hypothesis is that GSK3-β may play a
role to maintain functional MITF-M levels in melanocytes (41). It would be interesting
to know whether ATRA affects the level of GSK3-β, because ATRA can induce melanin
production in vitro (33). MITF then cooperates with LEF-1 and β-catenin to activate
gene transcription by binding to the dopachrome tautomerase (DCT) gene promoter, an
early melanoblast marker (51). Watabe et al. showed that Mitf mRNA levels increased
after 72 hrs ATRA treatment. (66) In a recent study, MITF have been shown to interact
with β-catenin to modulate melanocyte-specific gene transcription (67).
Anti-tumor agent – all trans-retinoic acid (ATRA)
ATRA is a derivative form of Vitamin A (retinol). The major source of ATRA in
the body is conversion of dietary β-carotene to retinal, and then it further oxidizes to
retinoic acid (RA), also called vitamin A acid (3, 55). It is known to be important to
embryonic inner ear development (36). In addition, it is involved in formation of visual
purple in the rod cells, which function to allow sight in dim light. It is also involved in
the formation of the three color pigments (red, green, and violet) in the cone cells, which
function in bright light to provide color vision (28). There are isoforms of retinoid
receptors, which belong to the family of nuclear receptors mediating the activity of
steroid and thyroid hormones vitamin D, prostaglandins, and certain drugs. Retinoids
have also been shown to have a role in prevention of cancer (32). Recent study has
shown that all trans-retinoic acid (ATRA) mediates the G1/ S arrest, and inhibition of
retinoic acid receptor (RAR) results in high percent S phase in normal human mammary
epithelial cells and lower G1 phase cells (42). This suggests that ATRA and RAR are
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vital regulators of the G1 to S phase cell cycle transition. After ATRA translocates by
cellular retinoic acid binding protein II (CRABP-II), a carrier protein (6), to the nucleus,
it binds to retinoid receptors and activates its target genes, including CRABP-II gene
expression (18). Some of the ATRA/RAR target genes that have been identified to be
up-regulated by RA/RAR pathway are activator protein-1 (AP-1), protein kinase calpha
(PKC), and T-box binding protein type 2 (Tbx-2) (33). ATRA promotes melanoma cell
differentiation by inducing PKCα and MITF mRNA level (66). Many studies have
shown that ATRA synergistically suppresses tumor development by induction of tumor
suppressor gene proteins, such as p53 and p105 (Rb or retinoblastoma protein), which are
strong inhibitors of cell proliferation (24, 29, 50). An interesting finding showed that
RAR, but not RXR (another isoform of retinoic acid receptor), is a competitor of TCF for
binding to β-catenin (56). This interaction was accelerated under the treatment of retinoic
acid. This study also showed that retinoic acid inhibits activation of β-catenin reporter
constructs (56). Interestingly, retinoic acid seems to have no effect on the cytoplasmic
regulation of β-catenin, suggesting it does not influence β-catenin degradation.
Retinoids have also been shown to regulate other genes that are involved in
normal cellular architecture, cellular adhesion, and cell-cell communication (11, 23).
ATRA also increased ICAM-1, a type of intracellular adhesion molecule, which may
involved in interaction between immune cells and melanoma (60). Adhesion modulated
by ATRA can be seen in our previous immunohistochemistry data (Fig. 1), which
showed that ATRA promotes localization of active β-catenin at the membrane for cellular
adhesion, as opposed to intracellular sites and restoring a more normal cellular
distribution of β-catenin. Therefore, RA may indirectly prevent β-catenin from inducing
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gene expression in the nucleus that leads to cell proliferation. In fact, our previous
Western Blot data showed that ATRA did not reduce the level of β-catenin but instead it
relocated and converted the active form of β-catenin to cell adhesion. (Henry & Delidow,
personal communication)

ß-Catenin
A

Nuclear
B

Vehicle

C

D

Retinoic Acid

Figure 1. Control and ATRA-treated B-16 mouse melanoma cells treated with anti-active-β-catenin (A-D)
primary antibodies. [A & C] Vehicle (DMSO) and RA-treated B-16 cells were stained with anti-active βcatenin and detected with Alexa-488 anti-mouse secondary antibody (green). Nuclei of vehicle and RAtreated B-16 cells were counter-stained with Propidium Iodide nuclear stain (red). Treatment with RA
reduced the number of cells. In vehicle-treated cells, active β-catenin is more evenly distributed throughout
the whole cell and especially in the nucleus of the vehicle-treated cells. In the RA-treated cells Active βcatenin is more clearly relocated to the membrane (see arrows, panel C). – Cara Henry

The effect of ATRA on β-catenin transcriptional activity in melanoma is still not
well understood. C-Myc and cyclin D1 protein expression are excellent markers for cell
proliferation; therefore, I will examine these β-catenin target genes proteins expression
under the treatment of ATRA in B16 cells. It is noteworthy that neither c-Myc nor cyclin
17

Fung Chan

5/2/2007

D1 is a direct ATRA target, thus, regulation of these genes in the presence of ATRA
suggests ATRA is able to interfere with a direct regulator, such as β-catenin. Previously,
we observed that ATRA reduces mouse B16 melanoma cell growth. Thus, we expected
the ATRA treated B16 mouse melanoma cells will have a lower c-Myc and cyclin D1
protein expression. We also need to investigate the transcriptional activity of β-catenin
under the treatment of ATRA by using a reporter gene assay. The reporter gene assay
can provide us direct evidence of transcriptional activity of β-catenin. Therefore, we
expected to see the β-catenin transcriptional activity is reduced by the ATRA treatment.
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Chapter Three
Materials and methods
Cell line
B16 mouse melanoma cells (F1 and F10) were obtained from American Type
Culture Collection (ATCC). Cells were grown in RPMI Medium 1640 (Gibco) This
medium contained 10% fetal bovine serum (Gibco Co.), and 1% penicillin-streptomycin
(Gibco). Cells were cultured in a humidified incubator with 5% CO2 at 37 °C.

Retinoic Acid
Vitamin-A-acid (all-trans-Retinoic acid, or ATRA) (Fluka) was purchased from
Sigma-Aldrich Co. A concentrated stock solution of ATRA (10 mM) was prepared in
dimethyl sulfoxide (DMSO) under subdued light environment to prevent photo-oxidation
of the retinoid. Fresh stock was prepared every 2 weeks. The final working
concentration (10-20 μM) was obtained by diluting the stock solution in tissue culture
medium.
Collection of cells
Cells were seeded at 2 × 105/100-mm tissue culture dish. The following day the
medium was replaced and cells were treated with 10-20 µM RA or an equal volume of
vehicle (DMSO). Cells were treated every 2 days and collected after 2 or 4 days of RA
treatment. Cells were collected by scraping and transferring into a 15-ml centrifuge tube.
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Cells were then spun down and the medium was decanted. The cell pellet was washed
with phosphate-buffered saline (PBS). The cells and the PBS were then transferred to a
micro-centrifuge tube and spun down. Cells were incubated in lysis buffer - (10 mM of
HEPES pH 7.5, 150 mM NaCl, 1.5 mM EDTA, 1% NP-40, and 2% (v/v) protease
inhibitor) for 5 min. After 5 min incubation, samples were spun down and the
supernatant (protein) were transferred to a fresh micro-centrifuge tube. The protein
concentration of each sample was determined by using the BCA protein assay kit from
Pierce. Protein samples (20 µg) were mixed with equal volume of gel loading dye and
denatured by boiling for 10 min.
Cell fractionation
Cells were collected as mentioned above. The cell pellet was re-suspended in an
appropriate amount of cell fractionation buffer (CFB) (20 mM of HEPES – pH 7.5, 10
mM KOAc pH 7.5, 1.5 mM MgCl2, and 2 % (v/v) the protease inhibitor) and incubated
on ice for 15 min. The cells were transferred to small dounce homogenizer and
homogenized using approximately 10 strokes. The cells were transferred back to the
original microtube and spun down at 5000 rpm at 4°C for 2 min. The supernatant
(cytoplasmic and membrane protein) was transferred to a new tube. The cell pellet was
washed 2 times in the CFB. The cell pellet containing nuclear protein was re-suspended
in PBS-NP40 (1X PBS, 1% NP-40, and 2% (v/v) protease inhibitor) and incubated on ice
for 15 min. The sample was spun down at 13,200 rpm for 1 min at 4°C and the
supernatant was collected into a new tube as nuclear protein.
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Plasmids, Transient transfection, and Reporter Gene Assay
Transient transfection was performed by using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. The cells were seeded the day before the
transfection at a density of 1 × 105 cells per well in 6 well plates. The following plasmids
were used in this assay: luciferase reporter constructs TOP flash (TCF reporter plasmid),
FOP flash (mutant TCF binding sites) (Upstate Biotechnology, Lake Placid, NY), point
mutated β catenin gene (ABC) (generous gift from Dr. Mayion Park) and thymidine
kinase (TK) renilla luciferase reporter vector (Promega) as a transfection control. The
following day, cells were transfected according to the manufacturer’s protocol: 10 ng of
TOP flash, FOP flash or ABC and 2 ng of control vectors were diluted in Opti-MEM I
medium (without serum and penicillin) (Invitrogen) in a 2 ml eppendorf tube. In another
2 ml eppendorf tube, 5 μl of Lipofectamine was diluted in Opti-MEM I medium (without
serum and penicillin) and incubated at room temperature for 5 min. After 5 min
incubation, the DNA-medium was mixed into the Lipofectamine 2000 (Promega) –
medium tube, and incubated for 20 min at room temperature. The growth medium was
replaced with Opti-MEM I medium (without serum and penicillin) and the DNALipofectamine 2000 complex was then add into the medium (1.5 ml). The cells were
transfected at 37°C in a CO2 incubator for 24 hrs. The growth medium was replaced and
the cells were grown for 24 more hrs or until they were ready to assay for luciferase
expression. After the cells were transfected, growth media was removed from the
cultured cells. Cultured cells were rinsed with in PBS, and then disrupted in 250 μl (for 6
well plate) of passive lysis buffer (provide by the Promega Dual-Luciferase Reporter
gene assay kits) by gentle rocking for 15 min at room temperature. To measure luciferase
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enzyme activity, 20 μl of lysates were transferred to a siliconized polypropylene tube.
One hundred μl of Luciferase assay reagent was added and mixed with the lysates, and
then the tube was placed in the luminometer and the flash signal was measured; after that
100 μl of Stop and Glow reagent was added and the glow signal (Renilla control) was
measured and recorded.
Western blotting
Cellular proteins denatured in SDS-loading buffer were loaded into wells of a
SDS gel (10% separating and 3% stacking) for electrophoresis. A BioRad Criterion cell
was used to run the gel electrophoresis at 100 V for 1 hr 45 min. Proteins were then
transferred at 100 V for 1 hr to nitrocellulose membranes (Osmonics Inc.) by using a
BioRad transfer cell. The membrane was incubated in blocking solution (Tris-buffered
saline containing 0.2% Tween 20 and 3% nonfat dry milk, TBST) for 1 hr. Blots were
then incubated with 1:1000 dilution of either rabbit polyclonal anti-c-Myc antibody (Cell
Signaling Technology Inc.) overnight at 4°C, or with 1 µg/ml mouse monoclonal antiCyclin D1 antibody (Upstate Inc.) for 1 hr at room temperature. They were then washed
two times in TBST for 5 min and incubated with 1:3000 dilution of secondary antibody
(horseradish peroxidase-conjugated anti-rabbit/ mouse IgG, Amersham Corp., according
to the source of the primary antibody) for 1 hr. The membranes were then washed three
times in 1X TBST, and signals were detected by use of the ECL kit from Amersham
Corp.
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Densitometry
Signals from the ECL and horseradish peroxidase were captured with Fuji X-ray
films. A Bio-Rad ChemiDOC was used to scan the proteins bands and the image was
then analyzed using Quantity One software.
Electrophoretic Mobility Shift Assay (EMSA)
The cells were collected using the same method as mentioned in “Collection of
cells”. The cells were then incubated in cell fractionation buffer (10 mM NaOH-HEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5% NP-40) for 15 min on ice. The
fractionated cells were then spun down at 800 x g (3000 rpm) for 5 min at 4°C. The
supernatants were discarded by aspiration. The nuclear pellets were then washed once
with washing buffer (10 mM NaOH-HEPES pH 7.9, 1.5 mM MgCl2, and 10 mM KCl)
and centrifuged, as above. The nuclear pellets were incubated in hypotonic salt buffer
(20 mM NaOH-HEPES pH 7.9, 420 mM NaCl, 1.5 mM EDTA, and 10% glycerol) for 30
min on ice and spun down at 10,000 x g (10,300 rpm) for 5 min at 4°C. The supernatants
were collected as nuclear proteins. Biotin labeled oligonucleotides containing the
following consensus sequences were purchased from Panomics, Inc.:
TCF/LEF sequence (5-CCTTTGATCTTCCTTTGATCTT-3),
LEF1 sequence (5-CCCATTTCCATGACGTCATGGTTA-3),
RAR (DR5) sequence (5-TCGAGGGTAGGGTTCACCGAAAGTTCACTCG-3).
Nuclear extracts from control and ATRA treated B16 cells (5 µg of protein) were
incubated with binding reagents from electrophoretic mobility shift assay (EMSA) kits
(Panomics, Inc.): 2.0 µl 5X binding buffer, 1.0 µg poly d (I-dC), 10 ng transcription
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factor (TF) probe, in a total reaction volume of 10 µl. The nuclear extracts were
incubated with poly d (I-C) for 5 min at room temperature before adding the transcription
factor probe. The binding reaction was allowed to incubate for 30 min at room
temperature. To detect preformed complexes, the samples were run on 6% nondenaturing polyacrylamide gels in 0.5×Tris/borate/EDTA pH 8.0 buffer at 120 V for 1 hr
30 min 4°C by using a BioRad Criterion Cell. Protein and DNA were then transferred to
a nylon membrane (Osmonics Inc.) at 300 mA for 30-45 min by using a BioRad transfer
cell. Oligonucleotides were covalently attached to the membrane by UV-crosslinking.
The DNA–protein complexes were detected on the membranes by the
chemiluminescence detection method (EMSA Kits User Manual, Panomics, Inc.)
followed by autography using a Fuji X-ray film for 2-10 min.

Data Analysis

Graphs are presented as mean ± standard error. Multiple group comparisons were
performed by one way ANOVA. Significance of correlation, p-Value, was analyzed by
one way ANOVA.
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Results
ATRA effects on β-catenin target gene expression: c-Myc and cyclin D1
The transcriptional function of the β-catenin in melanoma cells is still unclear. It
is known that cyclin D1 and c-Myc are target genes in the canonical Wnt pathway,
because of their role in regulation of the cell cycle and cell proliferation. Cyclin D1 is a
key regulator of progression through G1 phase during the cell cycle (52). C-Myc is a
transcription factor, which possess the ability to induce cell proliferation, differentiation
and tumorigenesis (12, 30, 31). Wnt signaling free and protect β-catenin and causes
accumulation of β-catenin inside the nucleus. The ultimate task of intracellular β-catenin
is to regulate the expression of genes, such as cyclin D1 and c-Myc. Therefore, we
expected there will be a high level of cyclin D1 and c-Myc protein expression in
melanoma cells. In contrast, reduction of these protein expressions is expected in ATRAtreated cells.
Western Blot analysis was used to examine the effect of ATRA on the protein
expression of the c-Myc and cyclin D1 in B16 F1 and F10 mouse melanoma cells.
Results showed that c-Myc protein levels were reduced by 15.5 % (p-value = 0.022) after
2 days treatment, and by 58.0% (p-value = 0.00006) after 4 days ATRA treatment in F1
cells compared to control. In F10 cells, c-Myc protein levels were reduced by 18.4% (pvalue = 0.0001) after 2 days treatment, and by 35.8% (p-value = 0.0049) after 4 days
ATRA treatment compared to control (Figure 2-1). Similarly, cyclin-D1 protein
expression also decreased after ATRA treatment. There was only a slight decreased in
cyclin D1 protein levels after 2 days ATRA treatments and it was reduced by 17.1% (pvalue = 0.004) in F1 cells and 5% (p-value = 0.79) in F10 cells. After 4 days of ATRA
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treatment, cyclin D1 protein levels were reduced by 31.1 % (p-value = 0.32) in F1 cells
and by 79.3% (p-value = 0.0037) in F10 cells (Figure 2-2).
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αTub
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Day 2
Day 4

C RA C RA
Day 2
Day 4
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0.6
0.4
0.2
0
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C
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R4
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C4
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C

Day 4

Figure 2-1. ATRA effects on β-catenin target genes protein expression Three independent duplicate
experiments were performed for statistical analysis, n=6. We found that c-Myc protein levels were reduced
by 20 % after day 2 and by 40% in both cell lines after day 4 of RA treatment compare to control. An
asterisk (*) indicates significant difference from the control, p < 0.05 or less. Bars represented mean ±
standard error. C= control, DMSO; RA= 20 μM ATRA.
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Figure 2-2. ATRA effects on β-catenin target genes protein expression. Three independent duplicate
experiments were performed for statistical analysis, n=6. We found that cyclin D1 protein levels were
reduced by 40% in both cell lines after day 4 of RA treatment compare to control. An asterisk (*) indicates
significant difference from the control, p < 0.05 or less. Bars represented mean ± standard error. C= control,
DMSO; RA= 20 μM ATRA.

MITF protein expression after treatment of ATRA
MITF is vital for the differentiation and survival of melanocytes. (14, 15) Watabe
et al. (2002) showed that 72 hrs of ATRA treatment increased the mRNA levels of PKCα
and MITF (66). Therefore, we investigated whether ATRA treatment could induce MITF
protein levels in B16 F1 and F10 mouse melanoma cells. Western Blot data showed that
27

Fung Chan

5/2/2007

MITF protein level was increased 4 folds after ATRA treatment compared to the control
in B16 F1 cells, but not after 4 days. In B16 F10 cells, the MITF protein level was
increased 2 fold after 2 days ATRA treatment, and increased 4 fold after 4 days. (Figure
2-3)
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Figure 2-3. ATRA effects on β-catenin target genes protein expression- MITF. Two independent
duplicate experiments were performed for statistical analysis, n=4 for day 2 and n=2 for day 4. We found
that MITF protein level was increased 4 fold in F1cells after day 2 of ATRA treatment compare to control.
In F10 cells, MITF protein level was increased 2 fold. An asterisk (*) indicates significant difference from
the control. Bars represented mean ± standard error.

28

Fung Chan

5/2/2007

Electrophoretic Mobility-Shift Assay
EMSA were performed to determine whether B16 nuclear extracts contain protein
complexes capable of binding DNA consensus elements for LEF-1 or TCF. Comparison
was made using equal amounts of nuclear extracts harvested from B16 cells treated with
or without ATRA (Figure 3). The binding of the proteins and biotinylated TCF/ LEF
DNA binding site is indicating by the arrow (Figure 3-1) (64). Unlabeled DNA probe
(cold probe) was added to validate specific binding. There is no specific pattern of the
band intensity. Anti-active β-catenin antibody was added in Figure 3-1 (lane 12), but
there was no super shift occurred. In Figure 3-2, specific bands indicated the binding of
B16 nuclear proteins to the LEF-1 probe. In Figure 3-3, RAR protein binding to the RAR
(D5) binding site occurred. The intensity of the bands was reduced after ATRA
treatment (lane 5&6), suggesting that RAR protein might be used and degraded after the
binding of ATRA. Together, these studies suggest B16 cells do have proteins that bind to
TCF/ LEF and the LEF-1 DNA binding site and there is regulation of binding by ATRA.
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Figure 3-1. EMSA. Nuclear extracts of the Hela cells (lane 2), the B16 F1
cells (lanes 3-6) and B16 F10 cells (lanes 7-11) were incubated with a
biotinylated probe (lanes 1-12). C= control and R= ATRA treated. Unlabeled
Cold probe was added as a specific competitor (lanes 11). Supershift was
performed using anti-active β-catenin antibody (upstate) (lane 12).
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Figure 3-2. EMSA. Nuclear extracts of the Hela cells (lanes 2) ),
the B16 F1 cells (lanes 3-6) and B16 F10 cells (lanes 7-11) were
incubated with a biotinylated probe (lanes 1-11). C= control and
R= ATRA treated Unlabeled Cold probe was added as a specific
competitor (lanes 11).
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Figure 3-3. EMSA. Nuclear extracts of the Hela cells (lanes 2), the
B16 F1 cells (lanes 3-6) and B16 F10 cells (lanes 7-11) were
incubated with a biotinylated probe (lanes 1-11). C= control and
R= ATRA treatedUnlabeled Cold probe was added as a specific
competitor (lanes 11).

Luciferase reporter gene assay

In order to investigate whether the β-catenin signaling pathway is active in tumor
cell lines, we chose to use a reporter gene assay, one of the methods to determine
transcriptional activity of specific transcription factors in vitro. The Western Blot
analysis can only show the presence of signaling pathway components, which cannot be
used as direct evidence for the transcriptional activity. We investigated the Wnt/ βcatenin pathway in B16 mouse melanoma cells by using reporter genes, TOP-flash (wild
type TCF/ LEF binding sites) and FOP-flash (mutated TCF/ LEF binding sites). In
transcriptional activation, active β-catenin binds to TCF/ LEF protein, and then this
protein complex binds to a TCF/ LEF DNA binding site, enhancing transcription of the
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luciferase gene. TOP-flash and FOP-flash were first used to identify activation of the
Wnt/ β-catenin signaling pathway in human colon cancer cell lines (62). Therefore, we
employed Caco cells (human colon cancer cell line) to determine the optimal amount of
the reporter plasmids that we need to use and the efficacy of our transfection. First, we
investigated whether we could successfully transfect Caco cells using Lipofectamine ™
2000 reagent; the plasmids that we we used for transfection were TOP- or FOP-flash
(negative control) and pRL-TK renilla (a transfection control driving constitutive
expression of renilla luciferase). We found that the Caco cells express considerable
luciferase 48 hr after transfection, regardless of the amount of reporter plasmids that we
used (Figure 4-1). Having established successful transfection in Caco cells, we used the
same technique in B16 mouse melanoma cells.
Reporter (TOP/FOP)/ TK renilla ratio in Caco cells

Relative luciferase activity

2.5

2

TOP 1:1

1.5

FOP 1:1
TOP 2:2
FOP 2:2
TOP 4:4
FOP 4:4

1

0.5

0

Figure 4-1. The reporter/ TK renilla ratio in Caco cells Caco cells were transfected with TOP-flash or
FOP-flash plasmid (control) and pRL-TK vector (transfection control) with the amount of plasmids
consisting at 1 μg, 2 μg, or 4 μg. Luciferase expression was assessed by a luminometer after 48 hrs of
transfection; n=4. Bar represented standard error.
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Activity of the Wnt/ β-catenin pathway in B16 mouse melanoma cells
We utilized the luciferase reporter plasmid TOP-flash to examine if the Wnt/ βcatenin signaling pathway is active in B16 cells. First, we transfected B16 F1 and F10
cells using the same method with two different ratios of TOP-flash or FOP-flash vs. pRLTK vector (2 or 4 μg of reporter plasmid: 2 μg of pRL-TK) (Figure 4-2). After choosing
the ratio (4 μg of reporter plasmid: 2 μg of pRL-TK), we transfected B16 cells along with
Caco cells as a positive control (Figure 4-3). We found that the TOP-flash luciferase
activities of both B16 cell levels were lower than their FOP-flash activity, while Caco
cells have much higher TOP-flash activity compared to their FOP-flash activity. These
results were unexpected; therefore, we tried to induce the level of β-catenin by inhibiting
its inhibitor, GSK3-β, using lithium chloride (LiCl) (63). We treated B16 cells with 10
μM LiCl after 24 hrs of transfection. Previously, we did not detect TCF-4 protein in B16
cells (unpublished observation), which suggested that B16 cells may not contain
complexes binding to a TCF consensus element. Therefore, we used a plasmid that
contains the LEF-1 binding site in the MITF promoter, Pmic (generous gift from Dr. L.
Larue) in B16 cells (Figure 4-4). Although treatment with LiCl increased the TOP-flash
and Pmic activity, FOP-flash activity was also increased by LiCl even more than the wild
type reporter genes. Because FOP-flash activity was a paradox, we transfected the B16
cells using the same method, and treating the B16 cells with 10 µM of ATRA or an equal
amount of DMSO after 24 hrs of transfection (Figure 4-5). We observed that the TOPflash activity in both B16 cell lines was slightly decreased by ATRA, but FOP-flash
activity in F10 cells was decreased after 24 hrs of ATRA treatment, and increased in F1
cells.
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Transfection in B16 F1 and F10 cells with various reporter/ TK renilla ratios
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Figure 4-2. Transfection of B16 cells by Lipofectamine ™ 2000 reagent. B16 cells were transfected
with TOP-flash or FOP-flash plasmid (control) and pRL-TK vector (transfection control), with the plasmid
ratios of 2 or 4 μg of reporter plasmid and 2 μg of pRL-TK. Luciferase expression was assessed by a
luminometer after 48 hrs of transfection; n=4. Bar represented standard error.
Transfection in B16 F1, F10 and Caco cells with TOP-and FOP-flash
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Figure 4-3. Transfection of B16 cells and Caco cells by Lipofectamine ™ 2000 reagent. B16 and Caco
cells were transfected with TOP-flash or FOP-flash plasmid (control) and pRL-TK vector (transfection
control), with the plasmid ratios of 4 μg of reporter plasmid and 2 μg of pRL-TK. Luciferase expression
was assessed by luminometer after 48 hrs of transfection; n=4. Bar represented standard error.
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TOP, Fop & Pmic + LiCl treatment
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Figure 4-4. LiCl treatment after 24 hrs of transfection in B16 cells. B16 cells were transfected in 6-well
plates with TOP-flash or FOP-flash plasmids (control) or Pmic and pRL-TK vector (transfection control),
with the plasmid ratios of 0.5 μg of reporter plasmid and 0.2 μg of pRL-TK. Luciferase expression was
assessed by luminometer after 48 hrs of transfection and LiCl treatment; n=1.
Transfection of TOP Fop & Pmic with RA treatment
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Figure 4-5. ATRA treatment after 24 hrs of transfection in B16 cells. B16 cells were transfected in 6well plates with TOP-flash or FOP-flash plasmids (control) or Pmic and pRL-TK vector (transfection
control), with the plasmid ratios of 0.5 μg of reporter plasmid and 0.2 μg of pRL-TK. Luciferase
expression was assessed by luminometer after 48 hrs of transfection and ATRA treatment; n=2. Bars
represented mean.
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These results were unexpected, leading us to test whether the ratio of reporter to
control plasmids might be a cause of poor detection of specific transcriptional activity.
Therefore, we tested ratios of reporter plasmids to the pRL-TK vector. A broader range
of pRL-TK: reporter plasmid ratios (1:2.5, 1:5, 1:10 and 1:100) were examined in B16
F10 cells (Figure 4-6). We noticed that when we transfected at 1:100 ratio of reporter
plasmid: pRL-TK renilla, the FOP-flash activity was much higher than the TOP-flash
activity. Thus, we selected the 1:10 ratio to be optimal.

Ratio test of Reporter plasmid vs Tk Renilla
1
0
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Relative luciferase activity
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TOP
5
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F10 1:10

F10 1:5

F10 1:100

Ratio
Figure 4-6. Ratio test of reporter plasmids vs. pRL-TK renilla vector in B16F10 cells. F10 cells were
transfected in 6-well plates with TOP-flash or FOP-flash plasmids (control) or Pmic and pRL-TK vectors
(transfection control), with the plasmid ratios of 0.5 μg of reporter plasmid and 0.2 μg, 0.1 μg, 0.05 μg and
0.005 μg of pRL-TK. Luciferase expression was assessed by a luminometer after 48 hrs of transfection;
n=2.

As a means of increasing the available proteins to transactivate the reporters, we
overexpressed active β-catenin to determine whether the B16 cells utilize the Wnt/ βcatenin signaling pathway. We obtained a point mutated active β-catenin (ABC) gene
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and Wnt-8 gene from Dr. Mayion Park. We expected to see TOP-flash activity increase
with the overexpression of ABC. We were not certain that Wnt-8 would induce the
downstream signaling cascade in B16 melanoma cells because these cells might not
express Frizzled 8a receptor (68) that binds to Wnt-8 protein. We received the human
melanoma cell line, FO-1, from Dr. L. Larue. We overexpressed ABC or Wnt-8 in F1,
F10 and FO-1 cell lines (Figure 4-7). Expression of FOP-flash activity was high in F10
cells, but it became even higher after overexpression of ABC. There was only a slight
increase of TOP-flash activity in F10 cells with the overexpressed ABC vector compared
to the control. In F1 cells, the pattern is similar to F10 cells, but the activity was not as
high. These results are consistent with what we observed above.
Overexpression of ABC & Wnt 8 in B16s and FO-1 cells
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Figure 4-7. Overexpression of ABC and Wnt 8 in B16 and FO-1 cells. Experiment was performed in
duplicate. B16 cells were transfected in 6-well plates with TOP flash or FOP flash plasmids (control) or
Pmic and pRL-TK vectors (transfection control), with the plasmids ratios of 10 ng of reporter plasmid, 10
ng of ABC or 10 ng of Wnt-8 and 2 ng of pRL-TK. Luciferase expression was assessed by a luminometer
after 48 hrs of transfection, n=2.
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Because FO-1 human melanoma cells exhibited an increased in TOP flash
activity, but not in FOP flash activity, when ABC was expressed, FO-1 cells were used as
a model to study the ATRA sensitivity of β-catenin transcriptional activity. FO-1 cells
have been studied in the field of immunology (61), but ATRA-sensitivity has not been
demonstrated. FO-1 cells (1X105) were plated in 6-well plates the day before
transfection. Then, transfected with TOP- or FOP-flash plasmids, in addition we
overexpressed ABC in the cells. After 24 hrs of transfection, the cells were treated with
10 µM of ATRA or the same amount of vehicle (Figure 4-8). The luciferase activity in
the ATRA treated cells decreased 30 % compared to the DMSO treated cells. In
addition, there was no difference when comparing ATRA treated cells to the untreated
cells.

Transfection of TOP/Fop flash with overexpression of active beta catenin with
ATRA day 1 treatment in FO-1 cells

Relative luciferase activity
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Figure 4-8. ATRA treatment after 24 hrs of transfection in FO-1 cells. FO-1 cells were transfected in 6-well
plates with 10ng of TOP flash or FOP flash plasmids (control) and 2 ng of pRL-TK vector (transfection
control), and overexpressed with 10 ng of ABC. Luciferase expression was assessed by luminometer after
48 hrs of transfection and 24 hrs of ATRA treatment, n=2.
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To validate the data, we repeated the experiment using the same method. We
performed the experiment in triplicate with 48 hrs of transfection and after 24 hrs of
ATRA treatment (Figure 4-9). These results showed that 10 µM of ATRA decreased the
TOP flash activity by 13%. With 20 µM of ATRA, TOP flash activity was reduced by
23%. This is an interesting trend, but the differences between the control and the ATRA
cells were not statistically significant.

FO-1 reporter assay with overexpression of active β-catenin after 24 hrs of ATRA treatment
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3.00

2.50
TOP 10 uM C
TOP 10 uM ATRA

2.00

TOP 20 uM C
TOP 20 uM ATRA
FOP 10 uM C
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0.50
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Treatment groups, n=6
Figure 4-9. ATRA treatment after 24 hrs of transfection in FO-1 cells. FO-1 cells were transfected in
6-well plates with 10 ng of TOP-flash or FOP-flash plasmids (control) and 2 ng of pRL-TK vector
(transfection control), and overexpressed with 10 ng of ABC. Luciferase expression was assessed by a
luminometer after 48 hrs of transfection and 24 hrs of ATRA treatment, n=6. Mean ± SEM.
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Discussion
The Wnt/ β-Catenin signaling pathway plays a pivotal role in embryonic
development among different species. It can also contribute to cancer formation, which
has been extensively studied in human colon cancer (44). The central molecule in the
Wnt signaling pathway is β-Catenin. It has been found that 30% of melanomas have βcatenin in their nuclei (65). Although there is evidence that β-Catenin is involved in
tumor formation, the transcriptional activity of β-Catenin in melanoma is still unclear.

Our previous results showed that ATRA relocated the β-catenin distribution from
nucleus to membrane in B16 cells (Henry and Delidow, personal communication). In
addition, other studies showed that disruption of β-catenin adhesion function can lead to
nuclear accumulation in melanoma (35). Our previous work showed that ATRA was able
to decrease the protein level of active β-catenin and LEF-1 in B16 cells (Kern and
Delidow, personal communication). We investigated whether the levels of the c-Myc and
cyclin D1 protein were reduced, in response to inhibition of β-catenin. Our Western Blot
data showed that the levels of c-Myc and cyclin D1 were reduced after 2 days and 4 days
ATRA treatment in B16 cells. Because these genes are not direct targets of ATRA, it
suggests they maybe reduced as a result of down regulated active β-catenin. Both c-Myc
and cyclin D1 can modulate cell proliferation and cell cycle (5, 13, 45, 47). Thus, the
reduction in c-Myc and cyclin D1 expression correlates well with the known effect of
ATRA on B16 cell proliferation (33).
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Not only were cell proliferation markers levels reduced, our previous result
showed that the β-Catenin partner and target protein, LEF-1, was also reduced after
ATRA treatment. In order to activate growth regulatory gene, β-Catenin is required to
couple with LEF-1 (21, 44, 48, 51). The reduction in LEF-1 expression suggests it is
more difficult for β-Catenin to co-activate gene transcription. On the other hand, MITF,
an important molecule that modulate melanocyte cell differentiation and survival, also
been shown to associate with LEF-1 and β-Catenin to regulate gene transcription (41).
MITF can associate with β-catenin in absence of LEF-1 to regulate melanocyte-specific
gene transcription that will redirect β-Catenin nuclear function from cell proliferation to
melanocyte-specific gene expression (67). In this study, ATRA induced MITF protein
level and other have shown that showed ATRA induces MITF mRNA expression (66). In
addition, ATRA was able to reduce LEF-1 expression and to promote differentiation (33).
Thus, ATRA inhibits melanoma progression by redirecting the B16 cells to differentiate,
in part through inducing MITF expression. However, these results are only down-stream
evidences of effects of ATRA on β-catenin, a direct evidence of β-catenin transcriptional
activity will be required.
We examined presence of β-catenin transcriptional complexes in B16 cells by
performing a gel shift assay. The gel shift assay results suggested that there are
transcription factors in B16 cells that bind to specific DNA elements (TCF/LEF and LEF1) consistent with transcriptional activity of β-catenin. Reporter gene assays were
performed to assess the transcriptional activity of β-catenin and its partner proteins TCF/
LEF. The TOP-flash activity was low compared to the negative control (FOP-flash) in
B16 cells. These results may suggest that B16 cells are not compatible with using FOP-
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flash as the negative control because of the possibility of binding to the mutant TCF
binding sites in the FOP-flash vector. On the other hand, we examined the transcriptional
activity of β-catenin in FO-1 cells (human melanoma cell lines). We noticed that this cell
line provides us with a consistently low response of the FOP flash activity, which means
that there is no non-specific binding of proteins to the mutated TCF binding sites in FO-1
cells. The results of reporter gene assays in FO-1 cells showed that TOP-flash does have
activity, which is induced in the presence of active β-catenin. In human colon cancer
cell, the transcription of TOP-flash construct was reduced by ATRA treatment. (69)
Similarly, we observed a reduction in TOP flash activity with presence of exogenous
ABC in FO-1 cells after treated with ATRA.
In conclusion, this study shows that ATRA reduces the expression of active βcatenin and its target genes (LEF-1, c-Myc, and cyclin D1) and increases MITF
expression in B16 cells. In addition, ATRA reduces the exogenous β-catenin
transcriptional activity in FO-1 cells. Thus, ATRA may inhibit melanoma cell growth by
decreasing active nuclear β-catenin protein levels and its nuclear activity, which
decreases the transcription of cyclin D1 and c-myc and ultimately resulting in slowed
cell-cycle progression.
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Chapter Four
Future Directions
Future directions for research based on this study should focus on the mechanism
by which ATRA affects β-catenin transcriptional activity in melanoma cells. In this
study, effects of ATRA on β-catenin transcriptional activity were demonstrated in FO-1
human melanoma cells, but expression of β-catenin target genes and proteins were not
examined. Therefore, Western Blot will be required to determine effects of ATRA on
protein expression of MITF, c-Myc, cyclin D1, LEF-1, and active β-catenin.
As mentioned in this study, MITF is an important molecule in melanocyte
development, survival, and may possess the ability to alter β-catenin nuclear function.
Therefore, study of whether MITF can improve or change the behavior of melanoma cells
to a more normal phenotype will be required. Alternatively, expression of LEF-1, a
partner of β-catenin, can be repressed using small interfering RNA (siRNA) and with/
without ATRA treatment to determine whether melanoma cells will continue to
proliferate in the absence of LEF-1 protein. In addition, RAR siRNA can be used to
determine whether siRNA reduced the ability of ATRA to decrease the nuclear activity of
β-catenin.
Different melanoma cell types may response to ATRA differently because of each
cell line does not have exact same signaling cascade that modulate their behavior. Thus,
investigation using mouse melanoma cell line may be not accurately depicting the
mechanism that occurs in human melanoma cell line. In future research, different human
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melanoma cell lines should be used and different pathway that response to ATRA should
also be examine.
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